OpenLB
Open Library of Bioscience
Advanced Search
Current opinion in endocrinology, diabetes, and obesity
Oct 01, 2024;31 (5): 184-190.

Epidemiologic changes in thyroid disease.

Gonzalo J Acosta, Naykky Singh Ospina, Juan P Brito
Author Information
  1. Gonzalo J Acosta: Division of Endocrinology, Department of Medicine, University of Florida, Gainesville, Florida.
  2. Naykky Singh Ospina: Division of Endocrinology, Department of Medicine, University of Florida, Gainesville, Florida.
  3. Juan P Brito: Knowledge and Evaluation Research Unit, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine.
PMID: 39087407 DOI: 10.1097/MED.0000000000000877

Abstract

PURPOSE OF REVIEW: To analyze the evolving epidemiologic trends in thyroid disease, focusing on risk factors, underlying drivers of these changes, and their implications on clinical practice and research priorities.
RECENT FINDINGS: Thyroid disease remains one of the most prevalent groups of disorders globally, and the shift in its frequency and distribution is multifactorial. The prevalence of hypothyroidism increases with age, although normal thyrotropin ranges appear to be age-dependent, raising concern for potentially inappropriate levothyroxine use. Hyperthyroidism and Graves' disease continue to be predominant in reproductive-age women but exhibit a milder phenotype at diagnosis. Thyroid nodules are increasingly found in asymptomatic patients, likely from more widespread use of neck and chest imaging. Thyroid cancer incidence has risen exponentially over the years, mostly driven by overdiagnosis of low-risk tumors; however, a small rise in incidence of higher risk tumors has been noted. Obesity appears to be a risk factor for thyroid cancer occurrence and more aggressive forms of the disease.
SUMMARY: Understanding epidemiologic trends in thyroid disease is crucial for guiding clinical practice and research efforts, aiming to optimize patient outcomes while preventing unnecessary and potentially harmful interventions.

References

  1. Zhang X, Wang X, Hu H, et al. Prevalence and trends of thyroid disease among adults, 1999–2018. Endocr Pract 2023; 29:875–880.
  2. Lisco G, De Tullio A, Triggiani D, et al. Iodine deficiency and iodine prophylaxis: an overview and update. Nutrients 2023; 15:1004.
  3. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014; 140:317–322.
  4. Morris LGT, Tuttle RM, Davies L. Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol Head Neck Surg 2016; 142:709–711.
  5. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1–133.
  6. Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol 2017; 14:587–595.
  7. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489–499.
  8. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; 18:988–1028.
  9. Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 2014; 99:923–931.
  10. Wyne KL, Nair L, Schneiderman CP, et al. Hypothyroidism prevalence in the United States: a retrospective study combining national health and nutrition examination survey and claims data, 2009–2019. J Endocr Soc 2022; 7:bvac172.
  11. Morris EJ, Vouri SM, Maraka S, Singh Ospina N. Trends and components of thyroid status evaluation in commercially insured adults in the United States, 2006–2020. J Clin Endocrinol Metab 2024; 109:611–618.
  12. Kantor ED, Rehm CD, Haas JS, et al. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 2015; 314:1818–1831.
  13. Taylor PN, Iqbal A, Minassian C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 2014; 174:32–39.
  14. Ross JS, Rohde S, Sangaralingham L, et al. Generic and brand-name thyroid hormone drug use among commercially insured and medicare beneficiaries, 2007 through 2016. J Clin Endocrinol Metab 2019; 104:2305–2314.
  15. Ayala IN, Soto Jacome C, Toro-Tobon D, et al. Appropriateness of levothyroxine prescription: a multicenter retrospective study. J Clin Endocrinol Metab 2024; 109:e765–e772.
  16. Ettleson MD, Ibarra S, Wan W, et al. Demographic, healthcare access, and dietary factors associated with thyroid hormone treatments for hypothyroidism. J Clin Endocrinol Metab 2023; 108:e1614–e1623.
  17. Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003–2005. Clin Endocrinol (Oxf) 2013; 78:768–776.
  18. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 1991; 229:415–420.
  19. Vanderpump MPJ. The epidemiology of thyroid disease. Br Med Bull 2011; 99:39–51.
  20. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016; 388:906–918.
  21. Bartalena L, Masiello E, Magri F, et al. The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest 2016; 39:1445–1451.
  22. Ippolito S, Cusini C, Lasalvia P, et al. Change in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest 2021; 44:1707–1718.
  23. Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 2014; 37:691–700.
  24. Perros P, Žarković M, Azzolini C, et al. PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 2015; 99:1531–1535.
  25. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328:553–559.
  26. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 126:226–231.
  27. Guth S, Theune U, Aberle J, et al. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest 2009; 39:699–706.
  28. Russ G, Leboulleux S, Leenhardt L, Hegedüs L. Thyroid incidentalomas: epidemiology, risk stratification with ultrasound and workup. Eur Thyroid J 2014; 3:154–163.
  29. Papaleontiou M, Haymart MR. Approach to and treatment of thyroid disorders in the elderly. Med Clin North Am 2012; 96:297–310.
  30. Kwong N, Medici M, Angell TE, et al. The influence of patient age on thyroid nodule formation, multinodularity, and thyroid cancer risk. J Clin Endocrinol Metab 2015; 100:4434–4440.
  31. Moon JH, Hyun MK, Lee JY, et al. Prevalence of thyroid nodules and their associated clinical parameters: a large-scale, multicenter-based health checkup study. Korean J Intern Med 2018; 33:753–762.
  32. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006; 295:2164–2167.
  33. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 2009; 115:3801–3807.
  34. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol 2016; 12:646–653.
  35. Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 2017; 317:1338–1348.
  36. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer ‘epidemic’—screening and overdiagnosis. N Engl J Med 2014; 371:1765–1767.
  37. Van den Bruel A, Francart J, Dubois C, et al. Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management. J Clin Endocrinol Metab 2013; 98:4063–4071.
  38. Janovsky CCPS, Bittencourt MS, Novais MAP de, et al. Thyroid cancer burden and economic impact on the Brazilian public health system. Arch Endocrinol Metab 2018; 62:537–544.
  39. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999–2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz , released in June 2023.
  40. Moleti M, Sturniolo G, Di Mauro M, et al. Female reproductive factors and differentiated thyroid cancer. Front Endocrinol (Lausanne) 2017; 8:111.
  41. Filetti S, Tuttle M, Leboulleux S, Alexander EK. Nontoxic diffuse goiter, nodular thyroid disorders, and thyroid malignancies. In: Williams Textbook of Endocrinology. 14th ed. Elsevier; 2020.
  42. Haymart MR, Banerjee M, Reyes-Gastelum D, et al. Thyroid ultrasound and the increase in diagnosis of low-risk thyroid cancer. J Clin Endocrinol Metab 2019; 104:785–792.
  43. LeClair K, Bell KJL, Furuya-Kanamori L, et al. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex in US thyroid cancer incidence compared with a meta-analysis of subclinical thyroid cancer rates at autopsy. JAMA Intern Med 2021; 181:1351–1358.
  44. Zevallos JP, Hartman CM, Kramer JR, et al. Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration: a study of the Veterans Affairs healthcare system. Cancer 2015; 121:741–746.
  45. Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds. Thyroid 2014; 24:472–479.
  46. Sosa JA, Hanna JW, Robinson KA, Lanman RB. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery 2013; 154:1420–1426. discussion 1426–7.
  47. Burgess JR. Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982–1997). Thyroid 2002; 12:141–149.
  48. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 2009; 18:784–791.
  49. Horn-Ross PL, Lichtensztajn DY, Clarke CA, et al. Continued rapid increase in thyroid cancer incidence in California: trends by patient, tumor, and neighborhood characteristics. Cancer Epidemiol Biomarkers Prev 2014; 23:1067–1079.
  50. National Center for Health Statistics (U.S.). National Health and Nutrition Examination Survey 2017–March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. 2021 [cited 2024 May 11]. Available at: https://stacks.cdc.gov/view/cdc/106273
  51. Rinaldi S, Lise M, Clavel-Chapelon F, et al. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer 2012; 131:1004–1014.
  52. Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev 2015; 16:1042–1054.
  53. Kitahara CM, McCullough ML, Franceschi S, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid 2016; 26:306–318.
  54. Kitahara CM, Pfeiffer RM, Sosa JA, Shiels MS. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995–2015). J Natl Cancer Inst 2020; 112:810–817.
  55. Kim HJ, Kim NK, Choi JH, et al. Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol (Oxf) 2013; 78:134–140.
  56. Trésallet C, Seman M, Tissier F, et al. The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices. Surgery 2014; 156:1145–1152.
  57. Choi JS, Kim EK, Moon HJ, Kwak JY. Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma. Endocrine 2015; 48:264–271.
  58. Suehs BT, Kamble P, Huang J, et al. Association of obesity with healthcare utilization and costs in a Medicare population. Curr Med Res Opin 2017; 33:2173–2180.
  59. Kitahara CM. Obesity, physical activity, and thyroid cancer risk: disentangling true associations from detection bias. Thyroid 2023; 33:276–277.
  60. Lee M, Powers AE, Morris LGT, Marti JL. Reversal in thyroid cancer incidence trends in the United States, 2000–2017. Thyroid 2020; 30:1226–1227.
  61. Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the United States: 2000–2018. Thyroid 2022; 32:560–570.
  62. Ahn HS, Welch HG. South Korea's thyroid-cancer ‘epidemic’—turning the tide. N Engl J Med 2015; 373:2389–2390.
  63. Filetti S, Durante C, Hartl D, Leboulleux S, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30:1856–1883.
  64. Al-Qurayshi Z, Khadra H, Chang K, et al. Risk and survival of patients with medullary thyroid cancer: national perspective. Oral Oncol 2018; 83:59–63.
  65. Chang EHE, Lutfi W, Feinglass J, et al. National trends in the surgical treatment of nonadvanced medullary thyroid cancer (MTC): an evaluation of adherence with the 2009 American Thyroid Association Guidelines. World J Surg 2016; 40:2930–2940.
  66. Raue F, Frank-Raue K. Epidemiology and clinical presentation of medullary thyroid carcinoma. Recent Results Cancer Res 2015; 204:61–90.
  67. Kotwal A, Erickson D, Geske JR, et al. Predicting outcomes in sporadic and hereditary medullary thyroid carcinoma over two decades. Thyroid 2021; 31:616–626.
  68. Janz TA, Neskey DM, Nguyen SA, Lentsch EJ. Is the incidence of anaplastic thyroid cancer increasing: a population-based epidemiology study. World J Otorhinolaryngol Head Neck Surg 2019; 5:34–40.
  69. Hvilsom GB, Londero SC, Hahn CH, et al. Anaplastic thyroid carcinoma in Denmark 1996–2012: a national prospective study of 219 patients. Cancer Epidemiol 2018; 53:65–71.

MeSH Term

Humans
Thyroid Diseases
Risk Factors
Prevalence
Incidence
Thyroid Neoplasms
Female
Obesity
Hypothyroidism
Hyperthyroidism
Male
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0diseasethyroidriskThyroidepidemiologictrendschangesclinicalpracticeresearchpotentiallyusecancerincidencetumorsPURPOSEOFREVIEW:analyzeevolvingfocusingfactorsunderlyingdriversimplicationsprioritiesRECENTFINDINGS:remainsoneprevalentgroupsdisordersgloballyshiftfrequencydistributionmultifactorialprevalencehypothyroidismincreasesagealthoughnormalthyrotropinrangesappearage-dependentraisingconcerninappropriatelevothyroxineHyperthyroidismGraves'continuepredominantreproductive-agewomenexhibitmilderphenotypediagnosisnodulesincreasinglyfoundasymptomaticpatientslikelywidespreadneckchestimagingrisenexponentiallyyearsmostlydrivenoverdiagnosislow-riskhoweversmallrisehighernotedObesityappearsfactoroccurrenceaggressiveformsSUMMARY:UnderstandingcrucialguidingeffortsaimingoptimizepatientoutcomespreventingunnecessaryharmfulinterventionsEpidemiologic

Similar Articles

Cited By